Safety and Effectiveness of Regorafenib (Correlate)
Correlate - Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings
Sponsor: Bayer
Listed as NCT02042144, this observational or N/A phase trial focuses on Neoplasms and remains completed. Sponsored by Bayer, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 8 earlier versions
-
Feb 2018 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Recruiting NA
-
Apr 2017 — Jun 2017 [monthly]
Recruiting NA
-
Feb 2017 — Apr 2017 [monthly]
Recruiting NA
Phase: PHASE4 → NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Multiple Locations, Argentina , Multiple Locations, Austria , Multiple Locations, Czechia , Multiple Locations, Denmark , Multiple Locations, France , Multiple Locations, Italy , Multiple Locations, Luxembourg , Multiple Locations, Mexico , Multiple Locations, Netherlands , Multiple Locations, Singapore and 3 more locations